Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
156 A B S T R A C T S / E U R O P E A N U R O L O G Y S U P P L E M E N T S 13 (2014) 103—194 with MIBC with Hazard Ratio 2.39 (CI 95% 1.03–8.55) p<0.05. Other parameters as a correct LD, number of implants, sex and age did not show statistically significant difference. No significant differences between the two groups for: age, sex, presence of carcinoma in situ, correct LD, positive nodes, number of implants and metastatic progression. Conclusions: Our study has shown that Progressive MIBC do not have a worse prognosis than Primary. Positive nodes in RC specimens seems to be an independent factor that decreases survival in patients with MIBC. In our series, parameters such as age, sex, correct LD, number of implants had not statistically significant differences regarding overall survival. P122 High visfatin expression predicts poor prognosis of upper tract urothelial carcinoma I-S. Lo, S-H Chen. Kaohsiung Medical University Hospital, Dept. of Urology, Kaohsiung, Taiwan Introduction & Objectives: Visfatin, a newly discovered adipocytokine, is a pro-inflammatory cytokine. This study aimed to evaluate the predictive value of visfatin on prognosis of patients with upper tract urothelial carcinoma. Material & Methods: One-hundred and five patients (median age = 64, range = 24–84 years) were included in this study. Visfatin expression in upper tract urothelial carcinoma tissues was analyzed by immunohistochemistry. Visfatin expression was correlated with clinicopathologic variables using the χ2 test. The prognostic value of visfatin for recurrence-free and cance-specific survival was evaluated by Kaplan-Meier estimates, and the significance of differences between curves was evaluated by the log-rank test. Cox regression model was also used to evaluate the hazard ratios of visfatin on survival. Results: High visfatin expression in upper tract urothelial carcinoma tissues was significantly correlated with tumor stage, grade and p53 expression. High visfatin expression was associated with poor recurrence-free and cancer-specific survival. Cox regression analysis also revealed that visfatin is an independent predictor of recurrencefree and cancer-specific survival. Conclusions: Our findings indicated that higher visfatin expression is a potential biomarker to predict patient survival. Further study is necessary to investigate the role of visfatin in the carcinogenesis of upper tract urothelial carcinoma. P123 Bladder tumour history, does it predict worse survival in upper tract transitional cell carcinoma? B. Akdoğan, B. Çıtamak, M. Altan, B. Özdemir, B. Haberal, H. Özen. Hacettepe University, Fac. of Medicine, Dept. of Urology, Ankara, Turkey Introduction & Objectives: To evaluate prognostic factors in upper tract transitional cell carcinoma (UUTTCC). Material & Methods: Since 1987, 127 patients (104 men, 23 women) with a mean age of 61.5±1.02 years have undergone nephroureterectomy and bladder cuff removal. Patient age, sex, anaemia, bladder tumour history, bladder recurrences, tumour stage, grade and location were evaluated as prognostic factors. Results: Mean follow up was 57.3±4.6 months. Overall 5-years survival was 60.6%. Univariate analysis revealed anaemia, positive bladTable 1. Cox regression analysis for 5-years overall survival in UUTTCC Parameter Age, years Sex Bladder tumour history Stage Grade Tumour localization Hazard ratio p 1.258 (0.72–2.19) 0.494 (0.22–1.07) 2.040 (1.07–3.87) 1.903 (1.034–3.504) 1.721 (1.146–2.584) 1.156 (0.610–2.19) 0.417 0.076 0.029 0.039 0.09 0.657 der tumour history, T stage, grade and tumour location in the upper tract as significant prognostic factors (HR=). On multivariate analysis T stage, grade and bladder tumour history were significant variables for the 5-years overall survival (HR=1.903, 1.721 and 2.04, respectively) (Table 1). Conclusions: Tumour stage and grade are well known prognostic factors as found in our study. Bladder tumour history is the most important prognostic parameter with highest HR in this series. Patients with bladder tumour should regularly and strictly followed-up for an upper tract recurrence which causes worse survival. P124 Cytoplasmic expression of iga1 protein is a factor of poor prognosis in urothelial bladder cancer B. Nodin, B. Jansson, E. Nilsson, C. Welinder, K. Jirstrom, A. Gaber. Facutly of Medicine, Dept. of Oncology and Pathology, Lund, Sweden Introduction & Objectives: Immunoglobulin A (IgA) has previously been found in various tumour tissue as well as in serum of epithelial cancer patients, and moreover IgA has been found to carry the Tn-antigen (GalNac α-Ser/Thr), which upregulated has been liked to poor prognosis. However to our knowledge, no study has previously investigated IgA expression and prognosis. In the present study, we examined the prognostic significance of IgA1 expression in a cohort comprising 110 cases of uroepithelial cancers. Material & Methods: Immunohistochemical expression of cytoplasmic IgA1 was evaluated in tissue microarrays with tumours from one retrospective cohort of uroepithelial cancer patients (n=110). Classification regression tree analysis was applied for selection of prognostic cutoff. Kaplan-Meier analysis, log rank test and Cox regression proportional hazards’ modeling were used to evaluate the impact of IgA1 overall survival (OS). Results: IgA1 expression could be evaluated in tumours from 99/110 cases. Cytoplasmic IgA1 expression correlated to more advanced Tstage (p<0.009), high grade tumours (p=0.008), male sex (p=0.003), loss of membranous expression of ezrin (p=0.030). Moreover, IgA1 expression was associated with an impaired OS (HR=1.99, 95% CI 1.16–3.43), remaining sigificant in multivariable analysis, adjusted for age, grade, T-stage and ezrin expression (HR=2.04, 95% CI 1.11– 3.76). Conclusions: The results from this study demosntrate, for the first time, that IgA1 expression is differentially expressed in urothelial bladder cancer, and that high expression is associated with unfavourable clinicopathological characteristics and independently predicts an impaired survival. The utility of IgA1 as a prognostic biomarker in transurethral resection specimens merits further investigation. P125 Epidemiology of bladder cancer in Niamey: An analysis of the Niger cancer registry data S. Mamoudou Garba 1 , H. Hami 2 , H. Mahamadou Zaki 1 , A. Soulaymani 2 , H. Nouhou 1 , A. Quyou 2 . 1 Laboratory of Pathological Anatomy and Cytology, Faculty of Health Sciences, Dept. of Abdou Moumouni University, Niamey, Niger; 2 Laboratory of Genetics and Biometry, Faculty of Science, Dept. of Ibn Tofaïl University, Kenitra, Morocco Introduction & Objectives: Bladder cancer is the sixth most common malignancy of the urinary tract in men and the 11th most common cancer in women. It is also the 9th leading cause of cancer death in men and the 14th most common cause of cancer death in women in Western Africa, with about 2 900 new cancer cases (1 741 men and 1 159 women) and 1 894 deaths from cancer in both sexes in 2012 (GLOBOCAN 2012). The aim of this study is to estimate the occurrence of bladder cancer in Niamey, in terms of incidence and describe its epidemiological characteristics.